MONTREAL, May 17 /CNW Telbec/ - Researchers at the CHUM Research Centre
(CRCHUM) and the Peter MacCallum Cancer Centre in Australia have
identified a new avenue for treating breast cancer.
In 20 to 30% of breast cancer patients, the over-expression of a
particular protein (human epidermal growth factor-2) is the main cause
of the proliferation of cancer cells. Over the past few years
Herceptin® (trastuzumab) has become the standard treatment for this
kind of cancer. While it is known that it blocks the activity of this
protein, its exact mechanism of action has remained a mystery.
Professor John Stagg, a CRCHUM researcher, Professor Mark J. Smyth, with
the Peter MacCallum Cancer Centre in Australia, and their colleagues* have discovered that in addition to blocking cell proliferation,
Herceptin also stimulates the production of interferons, which in turn
activate immune cells called lymphocytes.
For a full version of the press release: www.chumtl.qc.ca/presse.fr.html
SOURCE CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
For further information:
For more information and to obtain a copy of the study:
Centre hospitalier de l'Université de Montréal
+ 1 514-890-8000, extension 15380
Pager: + 1 514-860-7110